For Device Companies, Are FDA Headaches Ahead?
Guidant Corp.'s failure to get an approval recommendation on July 10 from the FDA's Circulatory Systems Device panel for its Contak CD/Easytrak system to treat congestive heart failure certainly wasn't bad news for other players in cardiac rhythm management (CRM). But for those companies that don't compete directly with Guidant in CRM--and perhaps even for those that do--the push-back by the FDA panel raised some eyebrows. It's entirely possible that the Guidant device simply didn't measure up--that the panel was correct in judging that it didn't meet the clinical end-points required to recommend approval. But some device industry executives worry about the future direction of the FDA's approval process.
You may also be interested in...
Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.